Get the Stockscreener App
86.62
0.97%
-0.85
After Hours:
86.50
-0.12
-0.14%
Dexcom Inc stock is traded at $86.62, with a volume of 1.86M.
It is down -0.97% in the last 24 hours and down -2.85% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$87.47
Open:
$87.38
24h Volume:
1.86M
Relative Volume:
0.41
Market Cap:
$32.69B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
37.05
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
-3.06%
1M Performance:
-2.85%
6M Performance:
+29.59%
1Y Performance:
+26.82%
1-Day Range:
$86.36
$87.64
1-Week Range:
$86.36
$90.39
52-Week Range:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
86.62 | 32.69B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom stock slips 2.01 percent ahead of the open - AD HOC NEWS
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow - Yahoo Finance
DexCom stock trades below its 52-week high as Truist lifts target - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced? - finance.yahoo.com
Dexcom stock falls 1.1 percent ahead of the open - AD HOC NEWS
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance UK
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer - Yahoo Finance
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - ACCESS Newswire
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration - TradingView
Dexcom stock holds near its yearly high after Q2 growth - AD HOC NEWS
Dexcom stock heads into the open after Nasdaq gains 0.45 percent - AD HOC NEWS
Dexcom Inc. stock gains on strong Q2 2026 growth and solid diabetes-tech momentum - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings and Promising Growth in the Medical Device Sector - directorstalkinterviews.com
Dexcom stock heads into the open after a 1.61 percent gain - ad-hoc-news.de
Dexcom Inc. stock gains on leadership change and strong recent performance - AD HOC NEWS
Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets - AD HOC NEWS
What Has Put DexCom (DXCM) Back in Focus? - Kalkine Media
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
TD Cowen reiterates Buy rating on DexCom, $95 price target - TradingView
Dexcom Inc. stock gains as insider sales and valuation come into focus - ad-hoc-news.de
Dexcom stock heads into the open after a 0.68% Nasdaq gain - AD HOC NEWS
Dexcom Inc. stock edges higher as Truist Securities reiterates Buy rating - AD HOC NEWS
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating - marketscreener.com
Dexcom stock heads into the open after a 1.0% gain - AD HOC NEWS
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing - marketscreener.com
Dexcom (NASDAQ: DXCM) director’s trust sells 8,089 shares in preset plan - Stock Titan
Dexcom (NASDAQ: DXCM) legal chief sells shares, keeps 99,885-share stake - Stock Titan
DexCom Inc (DXCM): GF Score of 95 Signals Strong Outperformance Potential - GuruFocus
Dexcom gives CFO Jereme Sylvain expanded role - MedTech Dive
Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026 - marketscreener.com
Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Yahoo Finance
Dexcom (DXCM) CFO trades stock under preset plan - Stock Titan
DexCom | 144: Notice of proposed sale of securities pursuant to Rule 144 - moomoo.com
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom appoints Glenn Boehnlein to board of directors - The Globe and Mail
DexCom (DXCM) Expands Board to 13 Directors with Appointment of Glenn S. Boehnlein - GuruFocus
Dexcom stock heads into the open after a 0.8% Nasdaq pullback - ad-hoc-news.de
Dexcom Appoints Glenn Boehnlein to Board of Directors - BioSpace
DexCom Expands Board with Glenn Boehnlein Appointment and Details Compensation Plan - Kalkine Media
DexCom, Inc. Announces Appointment of Glenn S. Boehnlein as Director, Member of Operations & Innovation Committee and Audit Committee, Effective September 10, 2026 - marketscreener.com
Dexcom (NASDAQ: DXCM) director gets 5,841-unit stock grant vesting over 3 years - Stock Titan
Dexcom (DXCM) director discloses 42-share trust stake - Stock Titan
DexCom appoints Glenn S. Boehnlein to Board and committees - TradingView
Dexcom (NASDAQ: DXCM) officer lines up six‑figure stock sale - Stock Titan
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Dexcom Inc. stock steadies near mid-range as conference outlines growth plan - ad-hoc-news.de
DexCom expects CONNECT study on type 2 diabetes to be published soon in a major journal. - Pluang
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):